{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:20:05Z","timestamp":1792120805070,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2208-2","type":"journal-article","created":{"date-parts":[[2016,2,27]],"date-time":"2016-02-27T07:48:15Z","timestamp":1456559295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey"],"prefix":"10.1186","volume":"16","author":[{"given":"Ruben","family":"Mesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Thyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Goldberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilan C.","family":"Paranagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Dubinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,27]]},"reference":[{"issue":"4","key":"2208_CR1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5045\/br.2014.49.4.211","volume":"49","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Choi CW, Won JH. The puzzle of myeloproliferative neoplasms: novel disease-specific mutations and new proposals for diagnostic criteria. Blood Res. 2014;49(4):211\u20133.","journal-title":"Blood Res"},{"issue":"24","key":"2208_CR2","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","volume":"124","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood. 2014;124(24):3529\u201337.","journal-title":"Blood"},{"issue":"3","key":"2208_CR3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","volume":"55","author":"J Mehta","year":"2014","unstructured":"Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595\u2013600.","journal-title":"Leuk Lymphoma"},{"issue":"33","key":"2208_CR4","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098\u2013103.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2208_CR5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401\u20138.","journal-title":"Blood"},{"issue":"24","key":"2208_CR6","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995\u20133001.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2208_CR7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","volume":"40","author":"A Falanga","year":"2014","unstructured":"Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348\u201358.","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"2208_CR8","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176\u201384.","journal-title":"Blood"},{"issue":"2","key":"2208_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.beha.2014.07.003","volume":"27","author":"M Bjorkholm","year":"2014","unstructured":"Bjorkholm M, Hultcrantz M, Derolf AR. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best Pract Res Clin Haematol. 2014;27(2):141\u201353.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"16","key":"2208_CR10","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. Blood. 2014;124(16):2507\u201313.","journal-title":"Blood"},{"issue":"1","key":"2208_CR11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68\u201376.","journal-title":"Cancer"},{"issue":"9","key":"2208_CR12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"issue":"9","key":"2208_CR13","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874\u201381.","journal-title":"Leukemia"},{"issue":"6","key":"2208_CR14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197\u2013201.","journal-title":"Blood"},{"issue":"21","key":"2208_CR15","first-page":"4067","volume":"122","author":"RM Emanuel","year":"2013","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian J-J, Slot S, Zweegman S, et al. Myeloproliferative (MPN) symptom burden response thresholds: assessment of MPN-SAF TSS quartiles as potential markers of symptom response [abstract]. Blood (American Society of Hematology 55th Annual Meeting abstract). 2013;122(21):4067.","journal-title":"Blood (American Society of Hematology 55th Annual Meeting abstract)"},{"key":"2208_CR16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","volume":"34","author":"H Geyer","year":"2016","unstructured":"Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, et al. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J Clin Oncol. 2016;34:151\u20139.","journal-title":"J Clin Oncol."},{"issue":"10","key":"2208_CR17","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3109\/10428194.2013.766732","volume":"54","author":"J Abelsson","year":"2013","unstructured":"Abelsson J, Andreasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, et al. Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma. 2013;54(10):2226\u201330.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2208_CR18","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s11136-014-0742-4","volume":"23","author":"MF Miller","year":"2014","unstructured":"Miller MF, Mullins CD, Onukwugha E, Golant M, Buzaglo JS. Discriminatory power of a 25-item distress screening tool: a cross-sectional survey of 251 cancer survivors. Qual Life Res. 2014;23(10):2855\u201363.","journal-title":"Qual Life Res"},{"key":"2208_CR19","unstructured":"Cancer Support Community. Cancer Experience Registry. 2015. https:\/\/www.cancerexperienceregistry.org\/ . Accessed 23 Feb 2016."},{"issue":"10","key":"2208_CR20","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356\u201363.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2208_CR21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","volume":"87","author":"R Vaidya","year":"2012","unstructured":"Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87(11):1003\u20135.","journal-title":"Am J Hematol"},{"issue":"5","key":"2208_CR22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","volume":"42","author":"E Pourcelot","year":"2014","unstructured":"Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360\u20138.","journal-title":"Exp Hematol"},{"key":"2208_CR23","unstructured":"Noss A. Household Income: 2013. American Community Survey Briefs. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2014\/acs\/acsbr13-02.pdf . 2014. Accessed 23 Feb 2016."},{"issue":"5","key":"2208_CR24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2208-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T03:07:34Z","timestamp":1498273654000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2208-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2208"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2208-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,27]]},"article-number":"167"}}